JP7386536B2 - アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用 - Google Patents

アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用 Download PDF

Info

Publication number
JP7386536B2
JP7386536B2 JP2020511364A JP2020511364A JP7386536B2 JP 7386536 B2 JP7386536 B2 JP 7386536B2 JP 2020511364 A JP2020511364 A JP 2020511364A JP 2020511364 A JP2020511364 A JP 2020511364A JP 7386536 B2 JP7386536 B2 JP 7386536B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
salt
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531530A5 (https=
JP2020531530A (ja
Inventor
スチュワート ディー． チップマン，
ジョン デマッテイ，
ラドワン キワン，
メリッサ エー． カチューラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corp filed Critical Dynavax Technologies Corp
Publication of JP2020531530A publication Critical patent/JP2020531530A/ja
Publication of JP2020531530A5 publication Critical patent/JP2020531530A5/ja
Priority to JP2023121658A priority Critical patent/JP2023129623A/ja
Application granted granted Critical
Publication of JP7386536B2 publication Critical patent/JP7386536B2/ja
Priority to JP2025083816A priority patent/JP2025131620A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020511364A 2017-08-22 2018-08-21 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用 Active JP7386536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023121658A JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JP2025083816A JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548848P 2017-08-22 2017-08-22
US62/548,848 2017-08-22
PCT/US2018/047323 WO2019040491A1 (en) 2017-08-22 2018-08-21 MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121658A Division JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2020531530A JP2020531530A (ja) 2020-11-05
JP2020531530A5 JP2020531530A5 (https=) 2021-09-16
JP7386536B2 true JP7386536B2 (ja) 2023-11-27

Family

ID=63638354

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511364A Active JP7386536B2 (ja) 2017-08-22 2018-08-21 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JP2023121658A Pending JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JP2025083816A Pending JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023121658A Pending JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JP2025083816A Pending JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用

Country Status (5)

Country Link
US (4) US10618896B2 (https=)
EP (2) EP4257198A3 (https=)
JP (3) JP7386536B2 (https=)
ES (1) ES2951817T3 (https=)
WO (1) WO2019040491A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951817T3 (es) 2017-08-22 2023-10-25 Dynavax Tech Corp Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
BR112022008039A2 (pt) 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US12564630B2 (en) * 2020-05-05 2026-03-03 Virovax Llc Vaccine adjuvants
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
JP7690221B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
CN113967256B (zh) * 2021-10-26 2022-09-30 山东大学 一种具有光热-化疗-免疫功能的纳米粒及其制备方法和应用
WO2023081237A1 (en) * 2021-11-03 2023-05-11 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
CN119136795A (zh) * 2021-11-10 2024-12-13 芝加哥大学 具有增强的疗效和降低的毒性的nfkb激活剂的作为佐剂的小分子免疫增强剂的缀合物
CN116731015B (zh) * 2023-05-18 2024-09-27 深圳威科森生物医药科技有限公司 咪唑并喹啉化合物及其制备方法、应用和组合物
EP4731632A1 (en) * 2023-06-21 2026-04-29 The Trustees of The University of Pennsylvania Toll-like receptor (tlr) agonist lipidoid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof
CN119320387B (zh) * 2024-12-19 2025-06-27 杭州天龙药业有限公司 基于Toll样受体激动剂的疫苗佐剂脂质化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294885A1 (en) 2011-05-18 2012-11-22 The University Of Kansas Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
WO2017058996A1 (en) 2015-09-29 2017-04-06 The University Of Chicago Polymer conjugate vaccines
JP2020532571A (ja) 2017-09-06 2020-11-12 バイオエヌテック エスエーＢｉｏｎｔｅｃｈ Ｓｅ Ｔｌｒ７のアゴニストとしての置換イミダゾキノリン
JP2021503005A (ja) 2017-11-14 2021-02-04 ダイナバックス テクノロジーズ コーポレイション Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JPH09500128A (ja) 1993-07-15 1997-01-07 ミネソタ マイニング アンド マニュファクチャリング カンパニー イミダゾ〔４，５−ｃ〕ピリジン−４−アミン
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP1615665A4 (en) 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7799800B2 (en) 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
US7884207B2 (en) 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
WO2014113634A1 (en) 2013-01-17 2014-07-24 University Of Kansas Toll-like receptor 2-agonistic lipopeptides, and method of making the same
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
ES2908150T3 (es) 2014-05-01 2022-04-27 Novartis Ag Compuestos y composiciones como agonistas del receptor de tipo Toll 7
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
EP3368092B9 (en) 2015-10-29 2020-07-29 Novartis AG Antibody conjugates comprising toll-like receptor agonist
AU2017376460A1 (en) 2016-12-13 2019-06-20 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
US10328895B2 (en) 2017-03-17 2019-06-25 Autoliv Asp, Inc. Seatbelt pretensioning retractor assembly including a pretensioner rod
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20180311334A1 (en) 2017-04-29 2018-11-01 Yale University Compositions and Methods for Inducing an Immune Response
ES2951817T3 (es) 2017-08-22 2023-10-25 Dynavax Tech Corp Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
US20120294885A1 (en) 2011-05-18 2012-11-22 The University Of Kansas Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
WO2017058996A1 (en) 2015-09-29 2017-04-06 The University Of Chicago Polymer conjugate vaccines
JP2020532571A (ja) 2017-09-06 2020-11-12 バイオエヌテック エスエーＢｉｏｎｔｅｃｈ Ｓｅ Ｔｌｒ７のアゴニストとしての置換イミダゾキノリン
JP2021503005A (ja) 2017-11-14 2021-02-04 ダイナバックス テクノロジーズ コーポレイション Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用

Also Published As

Publication number Publication date
US11124510B2 (en) 2021-09-21
US20220033400A1 (en) 2022-02-03
US10618896B2 (en) 2020-04-14
US20190062329A1 (en) 2019-02-28
US20240368155A1 (en) 2024-11-07
EP3672969B1 (en) 2023-07-05
WO2019040491A1 (en) 2019-02-28
EP4257198A3 (en) 2023-10-18
EP3672969A1 (en) 2020-07-01
JP2025131620A (ja) 2025-09-09
US11981670B2 (en) 2024-05-14
JP2020531530A (ja) 2020-11-05
US20200199124A1 (en) 2020-06-25
EP4257198A2 (en) 2023-10-11
ES2951817T3 (es) 2023-10-25
JP2023129623A (ja) 2023-09-14

Similar Documents

Publication Publication Date Title
JP7386536B2 (ja) アルキル鎖修飾イミダゾキノリンｔｌｒ７／８アゴニスト化合物およびその使用
JP6710727B2 (ja) 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP6257607B2 (ja) 癌免疫療法のための組成物および方法
CN108290845B (zh) 嘧啶化合物
EP1874342B1 (en) Compositions and methods for cancer immunotherapy
JP2013525431A (ja) 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
WO2005120574A1 (ja) 調節性細胞リガンドをリポソームに含有させてなる医薬
CN1921862A (zh) 包含至少一种toll样受体7或toll样受体8激动剂以及toll样受体4激动剂的免疫刺激组合物
CN114206378A (zh) 基于tlr受体配体的疫苗佐剂
KR102610798B1 (ko) 이중 규격 다공성 실리카 입자 기반의 암 예방 또는 치료용 조성물
Jyoti et al. played by nanoimmunoadjuvants
WO2025037627A1 (ja) Ｎｋｔ細胞リガンド含有リポソーム組成物を含む抗がん剤
CN116891828A (zh) 新型的免疫刺激分子及改造的外泌体及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230804

TRDD Decision of grant or rejection written
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7386536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150